AMCP Payer Perspectives on Management of Multiple Myeloma
Webinar Recorded on Dec. 7, 2021
Multiple myeloma (MM) is a hematologic cancer of plasma cells, currently estimated to afflict 160,000 people worldwide. Standard treatments include immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. The goals of treatment are to reduce disease burden with induction therapy, prolong durability of response with maintenance therapy, reduce treatment side-effects, and extend overall survival. Despite the approval of several therapeutic agents in the past decade that have led to improved response rates and increased survival, MM remains incurable. Payers are faced with several factors impacting MM care, including the preferred sequencing of treatment, total cost of care, ability to improve overall survival, and management of treatment side-effects. To understand the appropriate and cost effective treatment of MM, AMCP convened an expert panel of managed care stakeholders earlier this year. This webinar will review some of the key findings and approaches to managing this dynamic category.
- Dana Regan, MBA
Senior Director, Market Access and Patient Services
EVERSANA™ COMPLETE Commercialization